FDA Adverse Event Malfunction Summary report: N

XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM

MDR report key: 2981620 · Received February 27, 2013

Report

Report Number
2024168-2013-01164
Event Type
Malfunction
Date Received
February 27, 2013
Date of Event
February 5, 2013
Report Date
February 5, 2013
Manufacturer
AV-TEMECULA-CT
Product Code
NIQ
PMA / PMN Number
P110019
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

(B)(4). DURING PROCESSING OF THIS COMPLAINT, ATTEMPTS WERE MADE TO OBTAIN COMPLETE EVENT, PATIENT AND DEVICE INFORMATION. GUIDE WIRE: RUNTHROUGH NS. GUIDE CATH: PROFIT AL2 6F. THE DEVICE WAS RETURNED FOR EVALUATION. THE REPORTED LEAK WAS CONFIRMED. BASED ON VISUAL AND FUNCTIONAL ANALYSIS OF THE RETURNED DEVICE, THERE IS NO INDICATION OF A PRODUCT DEFICIENCY. A REVIEW OF THE LOT HISTORY RECORD REVEALED NO NON-CONFORMANCES THAT WOULD HAVE CONTRIBUTED TO THE REPORTED EVENT. REVIEW OF THE COMPLAINT HISTORY OF THE REPORTED LOT DID NOT INDICATE A MANUFACTURING ISSUE. BASED ON THE INFORMATION REVIEWED, THERE IS NO INDICATION OF A PRODUCT DEFICIENCY.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE PROCEDURE WAS TO TREAT A LESION LOCATED IN THE 99% STENOSED MID LEFT ANTERIOR DESCENDING ARTERY. NO PREDILATATION WAS PERFORMED PRIOR TO CROSSING A 2.5X15 MM XIENCE PRIME STENT DELIVERY SYSTEM (SDS) TO THE LESION. DURING SDS INFLATION, THE PRESSURE WOULD NOT INCREASE AT ALL, AND BLOOD WAS OBSERVED COMING INTO THE INFLATION LUMEN OF THE CATHETER. THE SDS WAS REMOVED FROM THE PATIENT WITHOUT ISSUE. A NON-ABBOTT STENT WAS DEPLOYED TO COMPLETE THE PROCEDURE. THERE WAS NO CLINICALLY SIGNIFICANT DELAY IN PROCEDURE AND NO ADVERSE PATIENT EFFECTS REPORTED. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
83357 XIENCE PRIME EVEROLIMUS ELUTING CORONARY STENT SYSTEM DRUG ELUTING CORONARY STENT SYSTEM NIQ AV-TEMECULA-CT 2091941

Patients

Seq Age Sex Outcome Treatment
1 64 YR